Oliver Krieter
About
Oliver Krieter is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Oliver Krieter has authored 25 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Molecular Biology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Oliver Krieter's work include Angiogenesis and VEGF in Cancer (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Oliver Krieter is often cited by papers focused on Angiogenesis and VEGF in Cancer (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Oliver Krieter collaborates with scholars based in Switzerland, Germany and Spain. Oliver Krieter's co-authors include Angelika Lahr, Jean Tessier, F. Stephen Hodi, William H. Sharfman, Morten Mau‐Sørensen, Michael Weller, Olivier Chinot, Ravi K. Amaravadi, Donald P. Lawrence and Ka Wang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Oliver Krieter
25 papers receiving 209 citations
Peers
Oliver Krieter
Eric Haines United States
Stephanie Royer‐Joo United States
Marnix Geukes Foppen Netherlands
Anna Orlova Austria
Dina Sakaeva Russia
Marta Escorihuela Spain
Nathalie Rioux-Leclerc France
Andy Futreal United States
Meri‐Sisko Vuoristo Finland
Dionysis Papadatos-Pastos United Kingdom
Citations per year, relative to Oliver Krieter Oliver Krieter (= 1×)
peers
Eric Haines
Countries citing papers authored by Oliver Krieter
Since
Specialization
Citations
This map shows the geographic impact of Oliver Krieter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Krieter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Krieter more than expected).
Fields of papers citing papers by Oliver Krieter
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Oliver Krieter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Krieter. The network helps show where Oliver Krieter may publish in the future.
Co-authorship network of co-authors of Oliver Krieter
This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Krieter. A scholar is included among the top collaborators of Oliver Krieter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Krieter. Oliver Krieter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yap, Timothy A., Nehal J. Lakhani, Amita Patnaik, et al.. (2024). First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.. Journal of Clinical Oncology. 42(16_suppl). 3005–3005.
2.
Ferreira, Cláudia S., Irina Klaman, Oliver Krieter, et al.. (2023). Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial. Frontiers in Oncology. 13. 1157596–1157596.
3.
Heil, Florian, Chia-Huey Ooi, Manuel Hidalgo, et al.. (2020). Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies. Translational Oncology. 14(2). 100984–100984.
4.
Mercier, François, et al.. (2020). Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. Journal of Pharmacokinetics and Pharmacodynamics. 47(6). 613–625.
5.
García‐Velloso, María José, Iván Peñuelas, Mariano Ponz‐Sarvisé, et al.. (2020). 286 Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4–1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer. Regular and Young Investigator Award Abstracts. A175.1–A175.
6.
Ceppi, Maurizio, Michael Hettich, Volker Teichgräber, et al.. (2020). Abstract 6135: Tumor-bearing non-human primates: An unrivaled model for translational cancer immunology research. Cancer Research. 80(16_Supplement). 6135–6135.
7.
Solecki, Gergely, Matthias Osswald, D. Weber, et al.. (2019). Differential Effects of Ang-2/VEGF-A Inhibiting Antibodies in Combination with Radio- or Chemotherapy in Glioma. Cancers. 11(3). 314–314.
8.
Wang, Ka, Tilman Schlothauer, Angelika Lahr, et al.. (2017). An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism. Cancer Chemotherapy and Pharmacology. 79(4). 661–671.
9.
Oaknin, Ana, I. Vergote, Isabelle Ray‐Coquard, et al.. (2017). Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179. Annals of Oncology. 28. v335–v335.
10.
Wagg, Jonathan, Oliver Krieter, Chia-Huey Ooi, et al.. (2017). Effect of molecular mechanisms mediating bevacizumab (BEV) and vanucizumab (VAN) on gastrointestinal perforation: Use of artificial neural networks for integrated data analysis.. Journal of Clinical Oncology. 35(15_suppl). e15108–e15108.
11.
Izar, Benjamin, William H. Sharfman, F. Stephen Hodi, et al.. (2017). A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine. 6(8). 1904–1914.
12.
Boetsch, Christophe, Kevin Smart, Benjamin Ribba, et al.. (2016). Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab.. Journal of Clinical Oncology. 34(15_suppl). e17042–e17042.
13.
Oaknin, Ana, Anne Floquet, Christophe Le Tourneau, et al.. (2015). Single agent vanucizumab (RO5520985) for platinum (Pt)-resistant recurrent ovarian cancer (OC): Results from a single arm extension phase of the phase I FIH study.. Journal of Clinical Oncology. 33(15_suppl). 5549–5549.
14.
Lassen, Ulrik, Olivier Chinot, Catherine McBain, et al.. (2015). Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro-Oncology. 17(7). 1007–1015.
15.
Friess, Thomas, et al.. (2015). Abstract C125: Preclinical pharmacodynamic biomarker and combination strategy of RG7386, a novel FAP-DR5 bispecific antibody for targeting solid tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). C125–C125.
16.
Nayak, Tapan K., C. Massard, Christophe Le Tourneau, et al.. (2015). 304 Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI. European Journal of Cancer. 51. S55–S56.
17.
Hidalgo, Manuel, Christophe Le Tourneau, Christophe Massard, et al.. (2014). Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2525–2525.
18.
Sharfman, William H., F. Stephen Hodi, Donald P. Lawrence, et al.. (2011). Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.. Journal of Clinical Oncology. 29(15_suppl). 8508–8508.
19.
Sessa, Cristiana, Dagmar Hess, Jean Bauer, et al.. (2008). Phase I study of the oral platinum agent satraplatin (S) in sequential combination with capecitabine (C) in patients with advanced solid tumours. Journal of Clinical Oncology. 26(15_suppl). 2560–2560.
20.
Gianni, Alessandro M., Carmelo Carlo‐Stella, Anna Guidetti, et al.. (2006). Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.. Blood. 108(11). 2730–2730.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Eric Haines Breakdown of academic impact, for papers by Stephanie Royer‐Joo Breakdown of academic impact, for papers by Marnix Geukes Foppen Breakdown of academic impact, for papers by Anna Orlova Breakdown of academic impact, for papers by Dina Sakaeva Breakdown of academic impact, for papers by Marta Escorihuela Breakdown of academic impact, for papers by Nathalie Rioux-Leclerc Breakdown of academic impact, for papers by Andy Futreal Breakdown of academic impact, for papers by Meri‐Sisko Vuoristo Breakdown of academic impact, for papers by Dionysis Papadatos-Pastos